Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pyxis Oncology (PYXS) Share-based Compensation (2024 - 2025)

Pyxis Oncology (PYXS) has disclosed Share-based Compensation for 2 consecutive years, with $3.1 million as the latest value for Q3 2025.

  • On a quarterly basis, Share-based Compensation rose 3.09% to $3.1 million in Q3 2025 year-over-year; TTM through Sep 2025 was $12.5 million, a N/A change, with the full-year FY2024 number at $12.9 million, down 23.61% from a year prior.
  • Share-based Compensation was $3.1 million for Q3 2025 at Pyxis Oncology, up from $3.0 million in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $4.3 million in Q1 2024 to a low of $2.8 million in Q4 2024.